SCHEMBL7411401

SCHEMBL7411401

Cc1ccc(-c2nc3cc(C)ccn3c2CCc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.47
KDM4E B2RXH2 2/20 0.47
SMN1; SMN2 Q16637 6/20 0.45
ALDH1A1 P00352 2/20 0.45
POLB P06746 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 5/20 0.44
PDE10A Q9Y233 1/20 0.44
NTRK1 P04629 1/20 0.43
HPGD P15428 1/20 0.43
EGFR P00533 1/20 0.43
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7233487 0.90 EGFR (0.48) RAB9AKDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL7241464 0.77 CYP11B1 (0.42) RAB9AKDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL7230585 0.76 GRIN1 (0.45) RAB9AKDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL7411403 0.74 MLKL (0.45) RAB9AKDM4ESMN1; SMN2KMT2ANPC1
SCHEMBL1691295 0.72 SMN1; SMN2 (0.51) RAB9AKDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL7231035 0.71 CYP11B1 (0.40) RAB9AKDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL7232083 0.71 ALDH1A1 (0.42) RAB9AKDM4ESMN1; SMN2ALDH1A1POLB
SCHEMBL8957996 0.71 NPC1 (0.76) RAB9ASMN1; SMN2ALDH1A1POLBKMT2A
SCHEMBL18136531 0.70 SMN1; SMN2 (0.64) RAB9AKDM4ESMN1; SMN2ALDH1A1NPC1
SCHEMBL1691156 0.69 SMN1; SMN2 (0.60) RAB9AKDM4ESMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002002557-A2 2-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2002-01-10 WO disclosed